



***Achromobacter* spp.: New Insights in Epidemiology, Pathogenicity, and Antimicrobial Therapy**

Guest Editor:

Dr. Lucie Amoureux

Department of Bacteriology,
University Hospital of Dijon,
21000 Dijon, France

Deadline for manuscript
submissions:

closed (30 December 2021)

Message from the Guest Editor

Dear Colleagues,

Achromobacter spp. are multidrug-resistant, non-fermenting Gram-negative bacilli increasingly being reported worldwide as opportunistic pathogens in patients with underlying conditions, especially cystic fibrosis (CF). The pathogenicity of these bacteria remains controversial among CF patients, and there are limited data concerning intrinsic or acquired resistance mechanisms and therapeutic options. Taxonomic studies describe a great diversity of species within the genus, with more than 20 species whose correct identification requires specific techniques not usually performed by the laboratories.

The aim of this Special Issue is to expand the current knowledge on the role of *Achromobacter* spp. in human health: sources of contamination and pathogenicity of the various species for CF or non-CF patients, intrinsic and acquired resistance mechanisms, and therapeutic options, including new antibiotics.

Keywords: *Achromobacter* spp.; epidemiology; identification; reservoirs; virulence; resistance; antimicrobial therapy





an Open Access Journal by MDPI

Editor-in-Chief

Dr. Nico Jehmlich

Department of Molecular
Systems Biology, UFZ-Helmholtz
Centre for Environmental
Research, 04318 Leipzig,
Germany

Message from the Editor-in-Chief

"Microorganism" merges the idea of the very small with the idea of the evolving reproducing organism is a unifying principle for the discipline of microbiology. Our journal recognizes the broadly diverse yet connected nature of microorganisms and provides an advanced publishing forum for original articles from scientists involved in high-quality basic and applied research on any prokaryotic or eukaryotic microorganism, and for research on the ecology, genomics and evolution of microbial communities as well as that exploring cultured microorganisms in the laboratory.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, PubAg, CAPlus / SciFinder, AGRIS, and other databases.

Journal Rank: JCR - Q2 (*Microbiology*) / CiteScore - Q2 (*Microbiology (medical)*)

Contact Us

Microorganisms Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/microorganisms
microorganisms@mdpi.com
X@Micro_MDPI